Key facts
- AllRock Bio’s last known valuation is $67.0M (Sep 2025).
- It has raised $50.0M; the latest was Early Stage VC ($50.0M) in Sep 2025.
- Notable investors include Versant Ventures, Westlake Village BioPartners.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for AllRock Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for AllRock Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AllRock Bio
Operator of drug development services intended to advance impactful therapies for cardiopulmonary diseases and improve the lives of patients worldwide. The company specializes in the development of novel therapies including their lead program ROC-101, ensuring advancements in treatments for pulmonary hypertension, interstitial lung diseases and other fibrotic conditions through cutting-edge science and strategic partnerships, enabling patients to benefit from comprehensive clinical trial planning and access to orally administered pan-ROCK inhibitors that address their specific needs and contribute to their overall well-being.
- Sector
- Healthcare
- HQ
- Natick, MA, United States
- Founded
- 2024
- Employees
- 5
- Website
- allrockbio.com/
- Ownership
- Privately Held (backing)
AllRock Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AllRock Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AllRock Bio in its N-PORT filings yet. We sweep new filings monthly.